


Express Mail Label No.: EL 862127122 US

Date of Deposit: October 16, 2001

Attorney Docket No. 14445-501



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 24 2001

TECH CENTER 1600/2900

APPLICANTS : Chalifour *et al.*
ASSIGNEE : Neurochem Inc.
SERIAL NUMBER: 09/724,842
FILING DATE : November 28, 2000
FOR : VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S AND
AMYLOID RELATED DISEASES

EXAMINER : Not Yet assigned

ART UNIT : 1642

October 16, 2001
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

- ☒ Supplemental Information Disclosure Statement (1 page);
- ☒ Supplemental Form PTO-1449 (submitted in duplicate; 1 page each);
- ☒ Copies of cited reference (B27); and
- ☒ Return postcard.


If the enclosed papers are considered incomplete, the Mail Room or the Application Branch is respectfully requested to contact the undersigned at 617 542-6000.

If any fees are to be assessed, the Commissioner is hereby authorized to charge the balance due to the undersigned's account, Deposit Account No. 50-0311, Reference No. 14445-501. A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Michel Morency, Limited Recognition
Barry J. Marenberg, Esq., Reg. No. 40,715
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
Telephone 617/348-3099
Attorney for Applicants

Date: October 16, 2001



Express Mail Label No.: EL 862126714 US
Date of Deposit: October 16, 2001

Attorney Docket No. 14445-501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chalifour et al.
ASSIGNEE: Neurochem, Inc.
SERIAL NUMBER: 09/724,842 EXAMINER: Not Yet Assigned
FILING DATE: November 28, 2000 ART UNIT: 1642
FOR: VACCINE FOR THE PREVENTION AND TREATMENT OF
ALZHEIMER'S AND AMYLOID RELATED DISEASES

October 16, 2001
Boston, Massachusetts

Application Processing Division's
Customer Correction Branch
Assistant Commissioner for Patents
Washington, D.C. 20231


TRANSMITTAL LETTER


Transmitted herewith for filing in the above-referenced patent application are the following documents:

- ☒ Request for corrected filing receipt;
- ☒ Copy of filing receipt marked with corrections; and
- ☒ Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts. Applicants believe that no fee is due. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Ref. No. 14445-501. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Michel Morency, Limited Recognition
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Chalifour et al.
 ASSIGNEE: Neurochem, Inc.
 SERIAL NUMBER: 09/724,842 EXAMINER: Not Yet Assigned
 FILING DATE: November 28, 2000 ART UNIT: 1642
 FOR: VACCINE FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S AND
 AMYLOID RELATED DISEASES

October 16, 2001
 Boston, Massachusetts

Application Processing Division's
 Customer Correction Branch
 Assistant Commissioner for Patents
 Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

- Applicants request a Corrected Filing Receipt for the above-mentioned patent application. Applicants enclose a copy of the Filing Receipt with the corrections noted thereon. Issuance of a corrected filing receipt is respectfully requested.
- There are errors with respect to the following data, which are:
 - ☒ incorrectly entered
 - and/or*
 - ☐ omitted.

Error in**Correct data**

- | | |
|--|---|
| <ol style="list-style-type: none"> <input type="checkbox"/> Applicants' name <input checked="" type="checkbox"/> Applicants' address <input type="checkbox"/> Title <input type="checkbox"/> Filing Date <input type="checkbox"/> Serial Number <input type="checkbox"/> Foreign/PCT Application <input type="checkbox"/> Continuing Data | <p>Xianqi Kong, Dollard-des-Ormeaux, CANADA</p> |
|--|---|

Error in

8. ☒ Other:

Attorney's Address:

Attorney Docket No.:


Correct data

Ivor R. Elrifi, Ph.D., Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111

14445-501

3. ☒ Applicants believe that no fee is due. However, the Commissioner is authorized to charge any fees that may be due to Deposit Account No. 50-0311, Ref. No. 14445-501.
4. Other documents:
- ☐ Copy of Limited Recognition Under 37 C.F.R. §10.9(b) for Michel Morency.


Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Michel Morency, Limited Recognition
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRA 1577945v1

MAY 07 2001



UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT & TRADEMARK OFFICE

MINTZ LEVIN, BOSTON
PATENT DOCKET DEPT.

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/724,842	11/28/2000	1642	1320	14445-501	7	45	5

CONFIRMATION NO. 6146

FILING RECEIPT



OC000000005984231

Date Mailed: 04/19/2001

~~000959~~
~~LAHIVE & COCKFIELD~~
~~28 STATE STREET~~
~~BOSTON, MA 02109~~

Ivor B. Elrifi, Ph.D., ESQ.
Mintz, Levin, Cohn, Ferns, Glovsky and Popeo, P.C.
One Financial Center
Boston, Ma 02111

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Robert Chalifour, Ile Bizard, CANADA;
Lise Hebert, Brossard, CANADA;
Xianqi Kong, Dollard-des-Ormeaux, CANADA; Ormeaux
Francine Gervais, Ile Bizard, CANADA;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/168,594 11/29/1999

Foreign Applications

If Required, Foreign Filing License Granted 04/18/2001

Projected Publication Date: N/A

Non-Publication Request: No


Early Publication Request: No

Title

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

424

Date: 04/19/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231